dc.creatorCORTEZ, Afonso José Pereira
dc.creatorDULLEY, Frederico Luiz
dc.creatorSABOYA, Rosaura
dc.creatorMENDRONE JÚNIOR, Alfredo
dc.creatorAMIGO FILHO, Ulisses
dc.creatorCORACIN, Fabio Luiz
dc.creatorBUCCHERI, Valéria
dc.creatorLINARDI, Camila da Cruz Gouveia
dc.creatorRUIZ, Milton Artur
dc.creatorCHAMONE, Dalton de Alencar Fischer
dc.date.accessioned2012-03-26T18:23:46Z
dc.date.accessioned2018-07-04T14:11:15Z
dc.date.available2012-03-26T18:23:46Z
dc.date.available2018-07-04T14:11:15Z
dc.date.created2012-03-26T18:23:46Z
dc.date.issued2011
dc.identifierRevista Brasileira de Hematologia e Hemoterapia, v.33, n.1, p.10-14, 2011
dc.identifier1516-8484
dc.identifierhttp://producao.usp.br/handle/BDPI/8927
dc.identifier10.5581/1516-8484.20110007
dc.identifierhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100007
dc.identifierhttp://www.scielo.br/pdf/rbhh/v33n1/v33n1a07.pdf
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1606935
dc.description.abstractBACKGROUND: Hodgkin's lymphoma has high rates of cure, but in 15% to 20% of general patients and between 35% and 40% of those in advanced stages, the disease will progress or will relapse after initial treatment. For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. OBJECTIVES: To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in a single transplant center. METHODS: A retrospective study was performed with data collected from patient charts. The analysis involved 106 classical Hodgkin's lymphoma patients who were consecutively submitted to high-dose chemotherapy followed by autologous transplants in a single institution from April 1993 to December 2006. RESULTS: The overall survival rates of this population at five and ten years were 86% and 70%, respectively. The disease-free survival was approximately 60% at five years. Four patients died of procedure-related causes but relapse of classical Hodgkin's lymphoma after transplant was the most frequent cause of death. Univariate analysis shows that sensitivity to pre-transplant treatment and hemoglobin < 10 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-type symptoms did not seem to affect overall survival. Lactic dehydrogenase and serum albumin concentrations analyzed at diagnosis did not influence patient survival either. CONCLUSION: Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. Refractory to treatment is a sign of worse prognosis. Additionally, a hemoglobin concentration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact on the survival of patients after transplant. As far as we know this relationship has not been previously reported.
dc.languageeng
dc.publisherAssociação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
dc.relationRevista Brasileira de Hematologia e Hemoterapia
dc.rightsCopyright Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
dc.rightsopenAccess
dc.subjectHodgkin's lymphoma
dc.subjectHematopoietic stem cell transplantation
dc.subjectAutologous transplantation
dc.subjectDoxorubicin
dc.subjectBleomycynm
dc.subjectVinblastine
dc.subjectDacarbazine
dc.subjectStudy retrospective
dc.titleAutologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución